Lifecare ASA

Share Issue/Capital Change • Sep 25, 2024

Lifecare ASA: Re-purchase of shares and warrants

Lifecare ASA: Re-purchase of shares and warrants

Reference is made to the contemplated consolidation of shares in Lifecare ASA

(the "Company") in a ratio of 13:1, as resolved by the extraordinary general

meeting of the Company held on 17 September 2024. Reference is further made to

the 54,519,478 warrants (the "Warrants") issued by the Company pursuant to

resolutions made by the extraordinary general meeting of the Company held on

16 May 2024. The Warrants shall, pursuant to their terms, be consolidated in

the same ratio as the shares (i.e. 13:1).

In order to deliver shares and warrants to persons who own a number of shares

and/or warrants that does not compute with the 13:1 ratio for the

consolidations, the Company will re-purchase up to 30.000 shares in the

Company and up to 7.500 Warrants in the Company, for delivery to such persons.

The purchases will be carried out as ordinary trades in the market.

About Lifecare:

Lifecare is a clinical stage medical sensor company developing technology for

sensing and monitoring of various body analytes. Lifecare's main focus is to

bring the next generation of Continuous Glucose Monitoring ("CGM") systems to

market. Lifecare enables osmotic pressure as sensing principle, combined with

the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR")

on the sensor body for read-out of pressure variations. Lifecare's sensor

technology is referred to as "Sencell" and is suitable for identifying and

monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

This information is subject to disclosure requirements pursuant to the

Norwegian Securities Trading Act section 5-12.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication at

2024-09-25 07:00 CEST.